REGADENOSON ANHYDROUS

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C15H18N8O5
Molecular Weight	390.354
Optical Activity	UNSPECIFIED
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of REGADENOSON ANHYDROUS

Structure Search

SMILES

CNC(=O)C1=CN(N=C1)C2=NC3=C(N=CN3[C@@H]4O[C@H](CO)[C@@H](O)[C@H]4O)C(N)=N2

InChI

InChIKey=LZPZPHGJDAGEJZ-AKAIJSEGSA-N

InChI=1S/C15H18N8O5/c1-17-13(27)6-2-19-23(3-6)15-20-11(16)8-12(21-15)22(5-18-8)14-10(26)9(25)7(4-24)28-14/h2-3,5,7,9-10,14,24-26H,4H2,1H3,(H,17,27)(H2,16,20,21)/t7-,9-,10-,14-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C15H18N8O5
Molecular Weight	390.354
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:34:22 UTC 2023` Edited by `admin` on `Fri Dec 15 15:34:22 UTC 2023`
Record UNII	7AXV542LZ4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

REGADENOSON ANHYDROUS

Common Name

English

regadenoson [INN]

Common Name

English

REGADENOSON [MART.]

Common Name

English

REGADENOSON [MI]

Common Name

English

Classification Tree Code System Code

NDF-RT

N0000178375

Created by admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023

WHO-ATC

C01EB21

Created by admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023

Code System Code Type Description

RXCUI

1546015

Created by admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023

PRIMARY

RxNorm

FDA UNII

7AXV542LZ4

Created by admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023

PRIMARY

PUBCHEM

219024

Created by admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023

PRIMARY

DAILYMED

7AXV542LZ4

Created by admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023

PRIMARY

NCI_THESAURUS

C171933

Created by admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023

PRIMARY

MERCK INDEX

m9517

Created by admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023

PRIMARY

Merck Index

EVMPD

SUB30494

Created by admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023

PRIMARY

EPA CompTox

DTXSID4057712

Created by admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023

PRIMARY

CAS

313348-27-5

Created by admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023

PRIMARY

INN

8488

Created by admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023

PRIMARY

DRUG BANK

DB06213

Created by admin on Fri Dec 15 15:34:22 UTC 2023 , Edited by admin on Fri Dec 15 15:34:22 UTC 2023

PRIMARY

Related Record Type Details


					Y154T023U0

ADENOSINE RECEPTOR A2A

TARGET -> AGONIST

Amount:


					7AXV542LZ4

REGADENOSON ANHYDROUS

EXCRETED UNCHANGED

Interaction Type:

AMOUNT EXCRETED

Qualification:

URINE

Amount:


					2XLN4Y044H

SALT/SOLVATE -> PARENT

Amount:


					2XLN4Y044H

SOLVATE->ANHYDROUS

Amount:

Related Record Type Details


					7AXV542LZ4

REGADENOSON ANHYDROUS

ACTIVE MOIETY

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Tmax	PHARMACOKINETIC				INTRAVENOUS ADMINISTRATION